trending Market Intelligence /marketintelligence/en/news-insights/trending/mrwwiybryc0hgrlnz7w7cq2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

US FDA flags violations at Alembic's Indian plant

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

US FDA flags violations at Alembic's Indian plant

Alembic Pharmaceuticals Ltd. said the U.S. Food and Drug Administration observed three violations at its formulation facility in India.

The U.S. regulator issued a Form 483 following an audit at the company's plant, located in India's Gujarat state.

A form 483 is issued when investigators observe any conditions or practices that may have violated the Food Drug and Cosmetic Act and could later pose health hazards to consumers.

Vadodara, Gujarat-based Alembic said none of the observations were related to data integrity or repetitive in nature.

The company said it will submit a response to the U.S. FDA shortly.